Barclays reiterated their sell rating on shares of Mazor Robotics (NASDAQ:MZOR) in a research report released on Tuesday, January 9th. Barclays currently has a $36.00 price objective on the medical instruments supplier’s stock.
Several other research analysts also recently commented on the stock. Zacks Investment Research raised shares of Mazor Robotics from a hold rating to a buy rating and set a $61.00 price target on the stock in a research note on Wednesday, December 13th. BidaskClub downgraded shares of Mazor Robotics from a strong-buy rating to a buy rating in a research report on Saturday, December 2nd. TheStreet raised shares of Mazor Robotics from a d rating to a c- rating in a research report on Wednesday, November 8th. Needham & Company LLC restated a hold rating on shares of Mazor Robotics in a report on Tuesday, November 7th. Finally, Ladenburg Thalmann Financial Services set a $67.00 price target on shares of Mazor Robotics and gave the company a buy rating in a report on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $43.50.
Shares of Mazor Robotics (NASDAQ MZOR) traded up $0.51 on Tuesday, hitting $59.31. 261,303 shares of the stock traded hands, compared to its average volume of 521,062. Mazor Robotics has a 1-year low of $20.69 and a 1-year high of $65.97. The stock has a market capitalization of $1,600.00, a P/E ratio of -84.73 and a beta of 0.96.
A number of hedge funds and other institutional investors have recently made changes to their positions in MZOR. Quantbot Technologies LP acquired a new stake in Mazor Robotics during the 2nd quarter valued at approximately $135,000. Advisor Group Inc. lifted its stake in Mazor Robotics by 365.8% during the 3rd quarter. Advisor Group Inc. now owns 2,795 shares of the medical instruments supplier’s stock valued at $138,000 after acquiring an additional 2,195 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in Mazor Robotics by 107.3% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,811 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 1,973 shares during the period. Halbert Hargrove Russell LLC acquired a new stake in Mazor Robotics during the 3rd quarter valued at approximately $214,000. Finally, Stratos Wealth Partners LTD. acquired a new stake in Mazor Robotics during the 3rd quarter valued at approximately $216,000. Institutional investors and hedge funds own 26.37% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Mazor Robotics (NASDAQ:MZOR) Earns Sell Rating from Barclays” was originally posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/mazor-robotics-mzor-sell-rating-reaffirmed-at-barclays/1824027.html.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.